"Drug Interactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
| Descriptor ID |
D004347
|
| MeSH Number(s) |
G07.690.773.968
|
| Concept/Terms |
Drug Interactions- Drug Interactions
- Drug Interaction
- Interaction, Drug
- Interactions, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Interactions".
Below are MeSH descriptors whose meaning is more specific than "Drug Interactions".
This graph shows the total number of publications written about "Drug Interactions" by people in this website by year, and whether "Drug Interactions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 5 | 5 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 5 | 5 |
| 2000 | 1 | 9 | 10 |
| 2001 | 2 | 4 | 6 |
| 2002 | 0 | 10 | 10 |
| 2003 | 0 | 9 | 9 |
| 2004 | 0 | 9 | 9 |
| 2005 | 0 | 15 | 15 |
| 2006 | 0 | 4 | 4 |
| 2007 | 2 | 6 | 8 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 8 | 8 |
| 2010 | 2 | 8 | 10 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 4 | 5 |
| 2013 | 1 | 4 | 5 |
| 2014 | 1 | 3 | 4 |
| 2015 | 1 | 5 | 6 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 6 | 7 |
| 2018 | 3 | 7 | 10 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 4 | 5 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
| 2025 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Interactions" by people in Profiles.
-
HIV-associated drug-resistant TB: expanded treatment options and emerging threats. Curr Opin HIV AIDS. 2026 Mar 01; 21(2):172-179.
-
Estimating risk of reported versus theoretical drug-drug interactions in headaches medicine: an exhaustive comparison between DrugBank and FAERS database for abortive and preventive combinations. J Oral Facial Pain Headache. 2025 Dec; 39(4):165-172.
-
Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic. Pharmacogenomics. 2024; 25(16-18):637-645.
-
Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint. Cardiol J. 2025; 32(1):83-89.
-
Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians. Expert Rev Cardiovasc Ther. 2024 Sep; 22(9):483-491.
-
A Calculated Risk: Evaluation of QTc Drug-Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score Calculator. Drug Saf. 2024 Dec; 47(12):1235-1243.
-
Kava (Piper methysticum) in the United States: the quiet rise of a substance with often subtle effects. Am J Drug Alcohol Abuse. 2023 01 02; 49(1):85-96.
-
Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. J Oncol Pharm Pract. 2022 Jun; 28(4):904-909.
-
Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nat Commun. 2021 03 12; 12(1):1660.
-
Impact of Protease Inhibitor-Based Antiretroviral Therapy on Tacrolimus Intrapatient Variability in HIV-Positive Kidney Transplant Recipients. Transplant Proc. 2021 Apr; 53(3):984-988.